Nuvation Bio (NUVB) Profit After Tax (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Profit After Tax of $3.9 million for Q1 2026, up 107.34% year-over-year from $1.9 million in Q1 2025, and up 110.68% quarter-over-quarter from -$36.6 million in Q4 2025.
Nuvation Bio (NUVB) Profit After Tax (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Profit After Tax for 7 consecutive years, with $3.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax rose 107.34% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at -$147.5 million (up 75.56% YoY), while the FY2025 annual figure was -$204.6 million, up 63.95% from the prior year.
- Profit After Tax climbed to $3.9 million in Q1 2026 per NUVB's latest filing, from -$36.6 million in the prior quarter.
- Across five years, Profit After Tax topped out at $3.9 million in Q1 2026 and bottomed at -$462.5 million in Q2 2024.
- Historically, Profit After Tax has averaged -$55.3 million across 5 years, with a median of -$28.3 million in 2022.
- Annual changes were most pronounced in 2024 — Profit After Tax slumped 2140.76% — and 2026, when it surged 107.34%.
- Nuvation Bio's Profit After Tax stood at -$18.3 million in 2022, then jumped by 43.53% to -$10.3 million in 2023, then plunged by 375.87% to -$49.1 million in 2024, then grew by 25.4% to -$36.6 million in 2025, then soared by 110.68% to $3.9 million in 2026.
- Business Quant data shows NUVB's Profit After Tax at $3.9 million in Q1 2026, -$36.6 million in Q4 2025, and -$55.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn | -63.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -63.77 Mn |
| Mar 31, 2026 | 3.91 Mn |
| Dec 31, 2025 | -36.59 Mn |
| Sep 30, 2025 | -55.79 Mn |
| Jun 30, 2025 | -59.01 Mn |
| Mar 31, 2025 | -53.24 Mn |
| Dec 31, 2024 | -49.05 Mn |
| Sep 30, 2024 | -38.56 Mn |
| Jun 30, 2024 | -462.49 Mn |
| Mar 31, 2024 | -14.79 Mn |
| Dec 31, 2023 | -10.31 Mn |
| Sep 30, 2023 | -18.55 Mn |
| Jun 30, 2023 | -20.64 Mn |
| Mar 31, 2023 | -21.73 Mn |
| Dec 31, 2022 | -18.25 Mn |
| Sep 30, 2022 | -28.34 Mn |
| Jun 30, 2022 | -34.86 Mn |
| Mar 31, 2022 | -21.29 Mn |
| Dec 31, 2021 | -25.13 Mn |
| Sep 30, 2021 | -21.98 Mn |